Fast Five Quiz: Idiopathic Pulmonary Fibrosis

Ani Kapoor, MD


April 30, 2020

The optimal medical therapy for IPF has not yet been found. The antifibrotic agents nintedanib and pirfenidone may reduce the rate of decline in forced vital capacity among patients with IPF over time. When choosing an antifibrotic agent, clinicians should consider patient preference, tolerance, potential side effects, drug interactions, and comorbidities.

Analysis of a double-blind, randomized, placebo-controlled trial showed interferon gamma-1b did not improve survival in patients with mild to moderate IPF. At present, it is not recommended for the treatment of IPF. 

According to the Centers for Disease Control and Prevention, patients with lung disease should receive influenza; pneumococcal; zoster; and tetanus, diphtheria, and pertussis vaccines. Smoking cessation counseling should also be considered a high priority in patients with IPF.

Lung transplantation has been shown to confer a survival benefit in patients with IPF over medical therapy. All patients diagnosed with IPF should be referred for lung transplantation evaluation, irrespective of their forced vital capacity.

Learn more about treatment options for patients with IPF.

For more information, refer to the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis - An Update of the 2011 Clinical Practice Guideline and the Japanese Guideline for the Treatment of Idiopathic Pulmonary Fibrosis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: